TherapeuticsMD, Inc. — Director's Dealing 2021

Oct 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-09-29

Reporting Person: Walker Marlan D (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-29	Restricted Stock Units	$0.00	A	57797	Acquired		Common Stock (57797)	Direct
2021-09-29	Non-Qualified Stock Option (right to buy)	$7.72	J	100000	Disposed	2025-06-04	Common Stock (100000)	Direct
2021-09-29	Non-Qualified Stock Option (right to buy)	$6.26	J	150000	Disposed	2026-09-22	Common Stock (150000)	Direct
2021-09-29	Non-Qualified Stock Option (right to buy)	$6.83	J	25000	Disposed	2027-03-14	Common Stock (25000)	Direct
2021-09-29	Non-Qualified Stock Option (right to buy)	$5.16	J	120000	Disposed	2028-03-15	Common Stock (120000)	Direct

Footnotes

F1: Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.

F3: Stock options exchanged for RSUs pursuant to the Option Exchange Program.

F4: Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, and 50,000 shares on the second anniversary date of the grant.

F5: Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, 50,000 shares on the second anniversary date of the grant, and 50,000 shares on the third anniversary date of the grant.

F6: Underlying shares were subject to vesting as follows: 8,333 shares on the first anniversary date of the grant, 8,333 shares on the second anniversary date of the grant, and 8,334 shares on the third anniversary date of the grant.

F7: Underlying shares were subject to vesting as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant.